Theralase Technologies Inc. V.TLT

Buyout before a FDA decision

[ScienceFirst]

After GSK's 2B$US move on BELLUS that was 2y before FDA approval, here's another example of a pharmas making a move 3 months before a FDA decision:

Astellas keeps the big buyouts rolling, inking $5.9B Iveric takeover ahead of FDA eye disease ruling

By Nick Paul Taylor May 1, 2023 08:13am

The multibillion-dollar biotech buyouts keep on coming. Astellas Pharma is the latest drugmaker to get in on the act, agreeing to pay $5.9 billion to buy Iveric Bio and establish itself as a player in an emerging eye disease niche. 

Iveric is less than three months away from learning whether the FDA will approve avacincaptad pegol

[Rumpl3StiltSkin]

Nice to see M&A activity is still going strong. I also think it is in a Pharmas interest to get to TLT early in the process, Probably after BTD.. But who knows? TLT has reained under the radar for a long long time. They might get AA before a Pharma raises their eyebrow... But hey AA still should happen this year.

[ScienceFirst]

Iveric Bio stock price was trading at 1$ in 2019.  It was bought for 38$ this morning (5.9B$). We have excellent data, no matter how you slice it.  There's no reason that DR above 30% @450-days doesn't lead to Breakthrough stays as it means we have data that is superior to competition.  This is all verifiable.  Not something made up because we want to get rich.  

[99942Apophis]

Thanks ScienceFirst,  I really like your posts on buyouts & formed partnership agreements.  I think when you find one that has a multiple growth profile similar to Theralase or if you could repost one that you found in the past I or you could do a hypothetical future share price, sounds like fun?